IE 11 is not supported. For an optimal experience visit our site on another browser.

Immunitor Therapy is a Potential Breakthrough Against Tuberculosis

/ Source: GlobeNewswire

VANCOUVER, Canada, Oct. 25, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that a clinical trial of V5 Immunitor oral vaccine was published earlier this month demonstrating an unexpected powerful effect against tuberculosis, including multi-drug-resistant tuberculosis (MDR-TB) and tuberculosis that is complicated by co-infection with HIV and hepatitis C (HCV). As advised in a September 16, 2010 press release, the Company has entered into a letter of intent to acquire Immunitor oral vaccine technology and products, subject to several conditions including the Company completing its regulatory filings.

V5 Immunitor is an oral vaccine designed and shown to be clinically effective for managing chronic hepatitis B and hepatitis C. The anti-tuberculosis effect has been revealed during a routine clinical trial of V5 in patients with chronic hepatitis C who happened to have tuberculosis. Not only was V5 effective on various liver disease endpoints in 19/20 of the patients, but also, several clinical endpoints associated with TB co-infection improved significantly during the one-month trial leading to discharge of 17 of the 20 patients enrolled. These results were published in the October 2010 edition of Journal of Vaccines and Vaccination, and are available in full text online at . An Immunitor press release is available online at .

Immunitor is continuing its clinical work on V5 and other products and updates on progress and further trials will be given accordingly. Immune Network has commenced work toward full regulatory compliance in Canada and USA so that the acquisition of Immunitor may proceed as planned. 

Further information is available on the web for Immune Network Ltd. () and for Immunitor ().

The Immune Network Ltd logo is available at

Safe Harbor Statement

The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

CONTACT: Immune Network Ltd.